Paper37037263
Recent progress in NIR-II fluorescence imaging-guided drug delivery for cancer theranostics.
Roy S and 4 others. Adv Drug Deliv Rev, 2023. Cited by 130 papers, by iCite.
Cite this record
ConductScience Library. Recent progress in NIR-II fluorescence imaging-guided drug delivery for cancer theranostics. Papers, record 37037263. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37037263
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Recent progress in NIR-II fluorescence imaging-guided drug delivery for cancer theranostics.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Antineoplastic Agents | Major topic |
| Nanoparticles | Major topic |
| Humans | |
| Precision Medicine | |
| Theranostic Nanomedicine | |
| Optical Imaging |
Source PubMed
Cited by55
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 130 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42740496 | Lactoferrin and Nanotechnology: New Insights Into Glioblastoma Therapy. | CNS Neurosci Ther | 2026 | https://conductscience.org/library/papers/42740496 | PubMed |
| 42684628 | NIR-II conjugated polymers for tumor sonodynamic therapy. | Discov Nano | 2026 | https://conductscience.org/library/papers/42684628 | PubMed |
| 42473560 | Progress in the Development of Metal-Organic Frameworks (MOFs) for Medical Imaging of Tumors: Prospects and Challenges. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42473560 | PubMed |
| 42211064 | Near-infrared II fluorescence imaging of PD-L1 and VEGF for assessing and early prediction of "T+A" therapeutic responsiveness in hepatocellular carcinoma. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/42211064 | PubMed |
| 42070503 | Multimodal strategies for diagnosing and treating thyroid cancer: Advances in basic and clinical research. | Transl Oncol | 2026 | https://conductscience.org/library/papers/42070503 | PubMed |
| 41993610 | Translational Models for Glioblastoma: Revolutionizing Drug Development and Personalized Medicine through Clinical Insights. | Theranostics | 2026 | https://conductscience.org/library/papers/41993610 | PubMed |
| 41975699 | Advances and Opportunities in NIR-II Endoscopy: From Diagnosis to Therapeutic Applications. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/41975699 | PubMed |
| 41869291 | High-Speed, Pixel-Super-resolved Compressive Second Near-Infrared Fluorescence In Vivo Imaging. | Research (Wash D C) | 2026 | https://conductscience.org/library/papers/41869291 | PubMed |
| 41809385 | Polysaccharide-functionalized gold, silver, and iron oxide nanoparticles for siRNA delivery: The role of artificial intelligence in design and optimization. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/41809385 | PubMed |
| 41790878 | Two-dimensional NIR-II AIE nanotheranostic probes with ultralarge Stokes shifts for surgical navigation and ablation of glioma. | Sci Adv | 2026 | https://conductscience.org/library/papers/41790878 | PubMed |
| 41788857 | Versatile Nanotherapeutics for Enhancing Sonodynamic Therapy/Chemotherapy of Thyroid Cancer through Remodeling Tumor Microenvironment and Synergistic Reactive Oxygen Species Augment. | Biomater Res | 2026 | https://conductscience.org/library/papers/41788857 | PubMed |
| 41611946 | Preliminary assessment of biodistribution and targeting of the fluorescent molecular probe Cy7-SYL3C in an EpCAM-positive colorectal cancer mouse model. | Sci Rep | 2026 | https://conductscience.org/library/papers/41611946 | PubMed |
| 41560814 | Metal-based nanomaterials achieve tumor treatment strategies by overcoming the blood-brain barrier of glioma and responding to the tumor microenvironment. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/41560814 | PubMed |
| 41511053 | Harnessing fluorescent probes for molecular diagnosis and theranostics of atherosclerosis. | Drug Deliv | 2026 | https://conductscience.org/library/papers/41511053 | PubMed |
| 41498647 | Stimuli-Responsive Supramolecular Biomaterials for Cancer Theranostics. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/41498647 | PubMed |
| 41476661 | Multi-Energy Integrated Photocatalysis for Antitumor Therapy. | Exploration (Beijing) | 2025 | https://conductscience.org/library/papers/41476661 | PubMed |
| 41427426 | Magnesium ion hydrogel enhances resistance to radiation-induced bone injury by modulating the bone immune microenvironment and promoting microvascularization. | Regen Biomater | 2025 | https://conductscience.org/library/papers/41427426 | PubMed |
| 41118004 | Emerging photothermal agents combined with immunotherapy for cancer treatment. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41118004 | PubMed |
| 41069763 | Responsive nanomedicine strategies achieve pancreatic cancer precise theranostics. | Bioact Mater | 2026 | https://conductscience.org/library/papers/41069763 | PubMed |
| 40958827 | Editorial: Micro-nano-materials for drug delivery, disease diagnosis, and therapeutic treatment. | Front Bioeng Biotechnol | 2025 | https://conductscience.org/library/papers/40958827 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37037263
GET https://conductscience.org/api/papers/v1/37037263/cited_by?page=2